Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354420 | 0.84 | TSHR (0.37) | TSHR | |
| SCHEMBL1853247 | 0.84 | TSHR (0.37) | TSHR | |
| SCHEMBL5162239 | 0.82 | TSHR (0.36) | TSHR | |
| SCHEMBL195840 | 0.79 | TSHR (0.39) | TSHR | |
| SCHEMBL21409479 | 0.78 | TSHR (0.38) | TSHR | |
| SCHEMBL28899667 | 0.77 | TSHR (0.32) | TSHR | |
| SCHEMBL28861483 | 0.76 | TSHR (0.37) | TSHR | |
| SCHEMBL27799496 | 0.76 | TSHR (0.37) | TSHR | |
| SCHEMBL1132226 | 0.75 | TSHR (0.36) | TSHR | |
| Formic Acid SCHEMBL28861142 | 0.75 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891472-B2 | Composition, production method for composition, and production method for unsaturated compound | RESONAC CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3842417-B1 | COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUND | RESONAC CORP (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-116583498-A | Blocked isocyanate compound | 株式会社力森诺科 | 2023-08-11 | — | — | CN | disclosed |
| US-11661474-B2 | Composition, production method for composition, and production method for unsaturated compound | SHOWA DENKO K.K. (JP) | 2023-05-30 | — | — | US | disclosed |
| EP-3842414-B1 | COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUND | SHOWA DENKO KK (JP) | 2023-04-05 | — | — | EP | disclosed |
| EP-3842416-B1 | COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUND | SHOWA DENKO KK (JP) | 2023-03-01 | — | — | EP | disclosed |
| CN-114929668-A | (meth) acrylate compound having isocyanate group and method for producing same | 昭和电工株式会社 | 2022-08-19 | — | — | CN | disclosed |
| US-20220119585-A1 | COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUND | SHOWA DENKO K.K. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3533813-B1 | GEL POLYMER ELECTROLYTE, METHOD FOR PRODUCING GEL POLYMER ELECTROLYTE AND ELECTROCHROMIC DEVICE CONTAINING SAME | LG CHEMICAL LTD (KR) | 2022-02-09 | — | — | EP | disclosed |
| US-20210292469-A1 | COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUND | SHOWA DENKO K.K. (JP) | 2021-09-23 | — | — | US | disclosed |
| EP-2676951-A1 | STABILIZED ISOCYANATE GROUP-CONTAINING ETHYLENE-BASED UNSATURATED COMPOUND | SHOWA DENKO K.K. (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-2676950-A1 | STABILIZED ISOCYANATE GROUP-CONTAINING ETHYLENE-BASED UNSATURATED COMPOUND | SHOWA DENKO K.K. (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-20130317252-A1 | STABILIZED ISOCYANATE GROUP-CONTAINING ETHYLENICALLY UNSATURATED COMPOUND | SHOWA DENKO K.K. (JP) | 2013-11-28 | — | — | US | disclosed |
| US-20130317248-A1 | STABILIZED ISOCYANATE GROUP-CONTAINING ETHYLENICALLY UNSATURATED COMPOUND | SHOWA DENKO K.K. (JP) | 2013-11-28 | — | — | US | disclosed |
| US-20120205234-A1 | POLYMERIZABLE MONOMER COMPOSITION AND METHOD FOR PREVENTING POLYMERIZATION | SHOWA DENKO K.K. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20110137066-A1 | PROCESS OF INHIBITING POLYMERIZATION OF ISOCYANATE GROUP-CONTAINING, ETHYLENICALLY UNSATURATED CARBOXYLATE COMPOUNDS, AND PROCESS FOR PRODUCING THE COMPOUNDS | SHOWA DENKO K.K. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2325166-A1 | METHOD FOR INHIBITING POLYMERIZATION OF ETHYLENICALLY UNSATURATED CARBOXYLIC ACID ESTER COMPOUND CONTAINING ISOCYANATE GROUP AND METHOD FOR PRODUCING ETHYLENICALLY UNSATURATED CARBOXYLIC ACID ESTER COMPOUND CONTAINING ISOCYANATE GROUP | Showa Denko K.K. (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20100099827-A1 | POLYMERIZABLE MONOMER COMPOSITION AND METHOD FOR PREVENTING POLYMERIZATION | SHOWA DENKO K.K. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2091994-A1 | POLYMERIZABLE MONOMER COMPOSITION AND METHOD FOR PREVENTING POLYMERIZATION | Showa Denko K.K. (JP) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008069256-A1 | POLYMERIZABLE MONOMER COMPOSITION AND METHOD FOR PREVENTING POLYMERIZATION | SHOWA DENKO K.K. (JP) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661474-B2 | Composition, production method for composition, and production method for unsaturated compound | ELOVL1, ACOX1, NCOA1 | TSHR 3345/4885 |
| US-20210292469-A1 | COMPOSITION, PRODUCTION METHOD FOR COMPOSITION, AND PRODUCTION METHOD FOR UNSATURATED COMPOUND | ACOX1, NCOA1, ELOVL1 | TSHR 3447/4885 |
| US-20110137066-A1 | PROCESS OF INHIBITING POLYMERIZATION OF ISOCYANATE GROUP-CONTAINING, ETHYLENICALLY UNSATURATED CARBOXYLATE COMPOUNDS, AND PROCESS FOR PRODUCING THE COMPOUNDS | ALKBH3, OGDH, IDH2 | TSHR 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.